TNF Pharmaceuticals (LTS:0A8D) Short-Term Debt & Capital Lease Obligation : $0.00 Mil (As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is TNF Pharmaceuticals Short-Term Debt & Capital Lease Obligation?

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. TNF Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was $0.00 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. TNF Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was $0.00 Mil.

TNF Pharmaceuticals Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for TNF Pharmaceuticals's Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TNF Pharmaceuticals Short-Term Debt & Capital Lease Obligation Chart

TNF Pharmaceuticals Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Short-Term Debt & Capital Lease Obligation

0.55

0.05

0.07

0.05

0.01

TNF Pharmaceuticals Quarterly Data
	Mar20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Short-Term Debt & Capital Lease Obligation	Get a 7-Day Free Trial															0.04	0.03	0.02	0.01	-

TNF Pharmaceuticals Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

TNF Pharmaceuticals Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of TNF Pharmaceuticals's Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

TNF Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TNF Pharmaceuticals Inc (LTS:0A8D) » Definitions » Short-Term Debt & Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

TNFA:USA

Address

1185 Avenue of the Americas, Suite 249, New York, NY, USA, 10036

Website

https://www.tnfpharma.com

TNF Pharmaceuticals Inc is a clinical-stage pharmaceutical company committed to extending a healthy lifespan. The company is developing and commercializing two therapeutic platforms, Isomyosamine and Supera-CBD. Isomyosamine is a small molecule that regulates the immunometabolic system to treat autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. It is being developed to treat age-related illnesses such as frailty and sarcopenia. Supera-CBD is a synthetic derivative of CBD being developed to treat various conditions, including epilepsy, pain, and anxiety/depression, through its effects on the CB2 receptor, opioid receptors, and monoamine oxidase enzyme type B. The company has one reportable segment focused on Isomyosamine.

TNF Pharmaceuticals Headlines

No Headlines